About the Company

Home » About DUSA » Board of Directors

Board of Directors

Jay M. Haft, Esq. (Chairman of the Board)

Jay M. Haft, Esq. is the Chairman of the Board of Directors. Since 2005, Mr. Haft has been a partner and a member of the Investment Committee of Columbus Nova, a private investment arm of the Renova Group. He was a senior corporate partner of the law firm of Parker, Duryee, Rosoff & Haft from 1989 to 1994 and was of counsel to Parker, Duryee, Rosoff & Haft and Reed Smith LLP until 2002. He is a strategic and financial consultant for growth-stage companies and is also active in international corporate finance mergers and acquisitions, having extensive experience in the Russian market where he has worked on growth strategies for companies looking to internationalize their business assets and enter international capital markets. He is also active in the non-profit sector as well, particularly in the areas of education and art. Mr. Haft has served on over 30 corporate boards, and is currently a member of the Board of Directors of Kingstone Companies, Inc., and DCAP Group Inc. He also serves on the Board of the U.S.-Russia Business Council and The Link Times Foundation, a private cultural historical foundation. Mr. Haft is a director of Ballantyne Cashmere, SpA and an advisor to Montezelmolo & Partners, an Italian family investment group.

Alfred Altomari

Alfred Altomari is currently President and Chief Executive Officer of Agile Therapeutics. He was previously the Chief Executive Officer of Barrier Therapeutics, Inc., a specialty pharmaceutical company since April of 2008 and a member of the company’s Board of Directors since January 2008, until the sale of the company in August 2008. Prior to joining Barrier, he had served in numerous executive roles in general management, commercial operations, business development, product launch preparations and finance within Johnson & Johnson from 1982 to 2003. Prior to his tenure at Johnson & Johnson, Mr. Altomari was Vice President/Franchise Head of Ortho-McNeil Pharmaceutical’s Women’s Health Care Franchise. He currently serves as a member of the Board of Directors of Agile Therapeutics, Auxilium Pharmaceuticals Inc, and Nitric BioTherapeutics. Mr. Altomari is also currently serving as a member of the Advisory Board of Le Bow College, the Business School of Drexel University.

David M. Bartash

David M. Bartash, serves as the Vice Chairman and Lead Director of the Board of Directors. He was the President and founder of Bartash and Company, a consulting company which, from 1990 to 2009, provided financial and scientific consulting services to the healthcare industry. Prior to founding Bartash and Company, Mr. Bartash spent over 20 years as a research analyst, and primarily, as a pharmaceutical analyst, at several major investment firms representing both the buy and the sell sides of Wall Street. Mr. Bartash serves on the Board of Directors of the Developmental Disabilities Institute, a not-for-profit organization providing educational, residential, and medical services to individuals with autism spectrum disorders. He served as Chairman for the Board of DDI until 2009, and currently services on the Executive, Finance and Building Committees. Mr. Bartash also serves on the Board of Directors of the DDI Foundation.

Alexander Casdin

Alexander Casdin is currently the Chief Financial Officer of Protox Therapeutics Corporation.  Prior to his position at Protox, he was Vice President, Finance of Amylin Pharmaceuticals, Inc.  In 2008, Mr. Casdin founded Casdin Advisors LLC where he served as a strategic advisor to the life sciences industry. Before founding Casdin Advisors, he worked as CEO and Portfolio Manager of Cooper Hill Partners, a healthcare investment fund. He joined Cooper Hill in September 2001 from Pequot Capital Management, where he was the Portfolio Manager of the Pequot Healthcare Fund. Prior to that, Mr. Casdin worked at the Dreyfus Corporation as a health care analyst, covering all areas of health care including pharmaceuticals, biotechnology, and medical device companies. He is currently a member of the advisory board of the Social Enterprise Program at Columbia Business School.

Robert F. Doman

Robert F. Doman, the Company's President and Chief Executive Officer, has been employed by DUSA since January 2005. From 2000 until 2004, Mr. Doman served as President of Leach Technology Group, the medical device division of Leach Holding Corporation. From 1999 to 2000, he was President, Device Products Development, of West Pharmaceutical Services, a manufacturer of systems and device components for parentally administered medicines and drugs. Prior to joining West Pharmaceutical Services, he worked for the Convatec division of Bristol-Myers Squibb from 1991 to 1999 in positions that included: Vice President, Worldwide Marketing and Business Development; Vice President and General Manager, U.S. Wound and Skin Care; and Vice President, U.S. Operations. Mr. Doman also spent 15 years with Johnson & Johnson in various sales, marketing and business development roles.

Paul J. Hondros

Paul Hondros is the President and Chief Executive Officer of AlphaOne Capital Partners, LLC, and its affiliate companies. Prior to founding AlphaOne in December, 2008, he was the founding President and Chief Executive Officer of Gartmore Global Investments and President and Chief Executive Officer of the Gartmore Group, a global asset management company. In 1998, he founded Villanova Capital, Inc., which operated until 2003, when it was merged into Gartmore Investment Management plc. Prior to founding Villanova Capital, Inc., he served briefly as President and Chief Operating Officer of Pilgrim Baxter & Associates, Ltd. From 1990 to 1997 he was President and Chief Operating Officer of Fidelity Investments’ Institutional Services Company and President and Chief Executive Officer of its Individual Investors groups. Mr. Hondros serves as the Chairman of the Board of Trustees of St. Joseph’s University, where he and his wife recently founded the Kinney Center for Autism Studies.

Magnus Moliteus

Magnus Moliteus is a consultant to the healthcare industry and Chairman of COM Consulting Inc., a privately held firm, which enhances Swedish-American relations particularly between health care companies. From 1995 to 2001, when he became a full-time consultant, Mr. Moliteus served as Executive Director of Invest in Sweden Agency, U.S., a Swedish government agency. From 1977 to 1990, he was Chief Executive Officer of Pharmacia, Inc. (now owned by Pfizer, Inc.), and from 1990 to 1995 he was Chief Executive Officer of Procordia US, Inc. Mr. Moliteus served as Chairman of the Swedish-American Chamber of Commerce, Inc. between 1988 and 1991, and remains an honorary director. He is currently a member of the Advisory Board of Eon Reality, Inc. and of e-pill, LLC. He is also Senior Advisor to Pharmadule Inc. and head of KAEL-Gemvax US and European operations.

David M. Wurzer

David M. Wurzer is currently the Managing Director of Investments at Connecticut Innovations, the State of Connecticut’s “venture capital arm,” where he has been in such a position since November 2009. From September 1997 until December 2007, he served as the Executive Vice President, Treasurer and Chief Financial Officer of CuraGen Corporation. Prior to his employment with CuraGen, from 1991 to 1997, he held management and executive level positions with Value Health, Inc., including Senior Vice President, Treasurer and Chief Financial Officer from February 1994 until September 1997. Additionally, from 1980 to 1991, Mr. Wurzer held managerial and accounting positions at Coopers & Lybrand, and its successor by merger, PricewaterhouseCoopers. Mr. Wurzer is currently a member of the board of directors of Strategic Diagnostics, Inc., Polybiotics, LLC, Axerion Therapeutics, Inc., and CyVek, Inc., and the not-for-profit theatre management company Playhouse Theatre Group.